There are currently 2030 clinical trials in Chicago, Illinois looking for participants to engage in research studies. Trials are conducted at various facilities, including Northwestern University, Rush University Medical Center, University of Chicago and University of Chicago Comprehensive Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy
NCT06247787
Recruiting
This phase I trial tests the safety, side effects, and best dose of imetelstat in combination with fludarabine and cytarabine in treating patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) or juvenile myelomonocytic leukemia (JMML) that has not responded to previous treatment (refractory) or that has come back after a period of improvement (recurrent). Imetelstat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs... Read More
Gender:
ALL
Ages:
Between 1 year and 18 years
Trial Updated:
08/15/2025
Locations: Lurie Children's Hospital-Chicago, Chicago, Illinois
Conditions: Recurrent Juvenile Myelomonocytic Leukemia, Refractory Juvenile Myelomonocytic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Myelodysplastic Syndrome, Refractory Childhood Acute Myeloid Leukemia, Refractory Childhood Myelodysplastic Syndrome
Register for Updates
A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
NCT06741228
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Generalized Anxiety Disorder - Voyage
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/15/2025
Locations: Uptown Research Institute, Chicago, Illinois
Conditions: Generalized Anxiety Disorder
Register for Updates
A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
NCT06439277
Recruiting
The goal of the study is to assess how tirzepatide impacts bodyweight and cardiovascular risk factors when used in conjunction with healthy nutrition and physical activity in adolescents with obesity and multiple weight related comorbidities. The study will last approximately 76 weeks and may include up to 23 visits. Participants who have completed the primary 72-week GPIX study and have been off treatment for no more than 12 weeks (including the 4-week safety follow-up period), will have the o... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
08/15/2025
Locations: Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Obesity, Weight Gain
Register for Updates
Movement Amplification Gait Training to Enhance Walking Balance Post-Stroke
NCT06400186
Recruiting
Stroke is a leading cause of disability in the United States, affecting approximately 795,000 people annually. The Veteran's Health Administration provides over 60,000 outpatient visits for stroke-related care annually at a cost of over $250 million. Among ambulatory people with chronic stroke (PwCS), impaired balance is a common health concern that substantially limits mobility (those with the worst balance walk the least). This project will explore adaptive strategies employed by PwCS in balan... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/15/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Chronic Hemiparetic Stroke
Register for Updates
A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)
NCT06941844
Recruiting
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating MM120 Compared to Placebo in Major Depressive Disorder - Emerge
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/15/2025
Locations: Uptown Research, Chicago, Illinois
Conditions: Major Depressive Disorder
Register for Updates
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
NCT05947500
Recruiting
This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, which is an enzyme that plays a role in repair of damaged deoxyribonucleic acid (DNA) as well as tumor c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Register for Updates
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular \[CV\] death, myocardial infarction \[MI\], and ischemic stroke).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/14/2025
Locations: Insight Hospital and Medical Center Chicago, Chicago, Illinois +1 locations
Conditions: Acute Coronary Syndrome
Register for Updates
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803
Recruiting
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/14/2025
Locations: Research Site, Chicago, Illinois
Conditions: Systemic Sclerosis, Scleroderma
Register for Updates
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS
NCT06008093
Recruiting
The purpose of the study is to assess the efficacy of durvalumab plus tremelimumab in combination with chemotherapy compared with pembrolizumab in combination with chemotherapy in metastatic NSCLC patients with non-squamous histology who have mutations and/or co-mutations in STK11, KEAP1, or KRAS.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
08/14/2025
Locations: Research Site, Chicago, Illinois +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
NCT05702034
Recruiting
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
08/14/2025
Locations: Rush University Medical Center, Chicago, Illinois +1 locations
Conditions: Ischemic Stroke; Ischemic Attack, Transient
Register for Updates
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
NCT05808764
Recruiting
This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.
Gender:
ALL
Ages:
19 days and below
Trial Updated:
08/14/2025
Locations: Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, Illinois
Conditions: Muscular Atrophy, Spinal
Register for Updates
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort
NCT07024823
Recruiting
This study will evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single ascending doses (SAD) and multiple ascending doses (MAD) of AZD4248 administered as an oral solution and intravenous (IV) infusion. Additionally, the study investigates the non-interventional feasibility of home measurement of serum creatinine in participants with diabetic kidney disease (DKD).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/14/2025
Locations: Research Site, Chicago, Illinois
Conditions: Chronic Kidney Disease
Register for Updates